Clinical trials: Moderate COPD
Chronic Obstructive Pulmonary Disease - COPD
Formoterol Dose Ranging Study (ACHIEVE Duaklir USA Phase IIb)
To assess the bronchodilation of three doses of formoterol fumarate (6 μg, 12 μg and 24 μg) twice daily (BID) administered via Pressair® compared to placebo and to open-label nebulized formoterol fumarate (20 μg and 40 μg).
- Trial name
- NCT02796651
- Testing
- Formoterol fumarate (6 μg), Formoterol furmarate (20 μg), Formoterol fumarate (12 μg)
- Where
- 20 sites in United States
- Volunteers
- 132 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
A Multi-centre Randomized Double Blind 52-week Study to Assess the Safety of QVA149 Compared to QAB149 in Patients With COPD Who Have Moderate to Severe Airflow Limitation
This study is to assess the safety and tolerability of two different doses of QVA149 and QAB149 in patients with moderate to severe airflow limitation.
- Trial name
- NCT01682863
- Testing
- QVA149, QAB149
- Where
- 86 sites in United States, Bulgaria and 5 more
- Volunteers
- 614 people
- Sponsor
- Novartis Pharmaceuticals
COPD Method Evaluation, Chronic Obstructive Pulmonary Disease Method Evaluation
Evaluation of an Oxygen Enhanced Magnetic Resonance Imaging Method on Patients With Chronic Obstructive Pulmonary Disease During 8 Weeks Treatment With Either Symbicort Turbuhaler or Oxis Turbuhaler
The main purpose of this study is to evaluate the sensitivity of a new oxygen enhanced magnetic resonance imaging (OE-MRI) method in detecting changes in the lungs of patients with moderate to severe chronic obstructive pulmonary…
- Trial name
- NCT01257048
- Testing
- Formoterol Turbuhaler, Budesonide/Formoterol Turbuhaler
- Where
- 2 sites in Sweden, United Kingdom
- Volunteers
- 34 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease (COPD)
Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00358436
- Testing
- Aclidinium bromide
- Where
- 120 sites in United States, Argentina and 5 more
- Volunteers
- 804 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive, COPD
Indacaterol Delivered Via a Single Dose Dry Powder Inhaler (SDDPI) in Chronic Obstructive Pulmonary Disease (COPD)
The study is designed to obtain safety and efficacy data on three dose levels of indacaterol when delivered via an SDDPI in patients with COPD.
- Conditions
- Pulmonary Disease, Chronic Obstructive, COPD, Lung Diseases, Obstructive
- Trial name
- NCT00396604
- Testing
- indacaterol maleate
- Where
- Belgium
- Volunteers
- 51 people
- Sponsor
- Novartis
Chronic Obstructive Pulmonary Disease
A Single Inhalation Dose Study to Assess Efficacy, Pharmacokinetics (PK), Safety and Tolerability of AZD8871 in Patients With Long-term Lung Diseases.
This study will evaluate the efficacy and safety data of AZD8871 in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT03645434
- Testing
- AZD8871, Anoro® Ellipta®
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 73 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
Dose Finding Study of Nemiralisib (GSK2269557) in Subjects With an Acute Moderate or Severe Exacerbation of Chronic Obstructive Pulmonary Disease (COPD)
Nemiralisib is being developed as an anti-inflammatory drug for the treatment of inflammatory airways disease. This study is designed to assess the dose response, efficacy, safety, and pharmacokinetics of nemiralisib across a…
- Trial name
- NCT03345407
- Testing
- Nemiralisib ELLIPTA 50 µg, Nemiralisib ELLIPTA 100 µg, Nemiralisib ELLIPTA 250 µg
- Where
- 161 sites in United States, Argentina and 14 more
- Volunteers
- 943 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Comparative Study of Umeclidinium/Vilanterol (UMEC/VI) in a Fixed Dose Combination With Indacaterol Plus Tiotropium
This is a Phase IIIb multicentre, randomised, blinded, triple dummy, parallel group study to evaluate the efficacy and safety of UMEC/VI inhalation powder (62.5/25 microgram [mcg] Once daily [QD]) when administered via ELLIPTA®…
- Trial name
- NCT02257385
- Testing
- UMEC/VI, Tiotropium, Indacaterol
- Where
- 84 sites in Argentina, Chile and 10 more
- Volunteers
- 967 people
- Sponsor
- GlaxoSmithKline
Pulmonary Disease, Chronic Obstructive
Study to Evaluate the Safety and Pharmacokinetics of Inhaled Ciprofloxacin in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Objectives of the study are to investigate the safety, tolerability and levels of ciprofloxacin in the lung after single and multiple inhalative administration to patients with moderate to severe COPD (stage II-III according to…
- Trial name
- NCT00961038
- Testing
- Ciprofloxacin (PulmoSphere, BAYQ3939)
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- Bayer
Chronic Obstructive Pulmonary Disease
PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers
The purpose of the study is to obtain pharmacokinetics, safety and tolerability data after single administrations of CHF6001 in subjects with mild, moderate and severe renal impairment as well as healthy volunteers under the same…
- Trial name
- NCT05431426
- Testing
- CH6001
- Where
- Bulgaria
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Asthma Copd
A Multicenter, Randomized, Parallel, Two-Period, Non-Inferiority Study of EurofarmavsAlenia in Asthma and COPD Treatment
A phase III study, multicenter, randomized, parallel, open, two-period, comparative non-inferiority of Eurofarma versus Alenia® in the treatment of moderate to severe persistent asthma with and without obstructive pulmonary…
- Trial name
- ESPIRE (NCT04233190)
- Testing
- Alenia® 12mcg + 400mcg / Alenia® 6mcg + 200mcg
- Where
- Brazil
- Volunteers
- 472 people
- Sponsor
- Eurofarma Laboratorios S.A.
Chronic Obstructive Pulmonary Disease
Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)
The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease…
- Trial name
- NCT00970268
- Testing
- Aclidinium bromide
- Where
- 83 sites in United States, Canada
- Volunteers
- 291 people
- Sponsor
- AstraZeneca